Background: Serankottai nei is a popular Siddha drug, used in the treatment of lung infections including tuberculosis, autoimmune joint diseases (rheumatoid arthritis, degenerative osteoarthritis), cancers and neurological pain. Objective: To standardize serankottai nei and to screen its in-vitro antitubercular activity of in H37Rv strain. Materials and Methods: Serankottai nei, a medicated ghee preparation was procured from the SKM Siddha and Ayurveda Co India Ltd, Erode, Tamil Nadu. Unsaponifiable matter (USM) from the ghee preparation was separated and preliminary phytochemical screening was done. Further, USM was dissolved in 10 ml of chloroform and 3 and 6 µl of the above sample was applied for HPTLC fingerprint, which was developed in toluene: ethyl acetate (9.0:1.0). The developed plates were scanned under UV 254 nm, 366 nm, 540 nm and 620 nm post derivatization. R f , colour of the spots and densitometric scan were recorded. Different doses of USM were screened for in-vitro antitubercular activity against H37Rv strain using Alamar Blue Dye method. Results: Phytochemical screening of 8% w/w USM obtained from serankottai nei showed presence of alkaloid, phenol, steroid and terpenoid. In HPTLC, there were 15, 5 and 7 peaks at 254 nm, 366 nm and 620 nm respectively. The Minimum Inhibitory Concentration (MIC) against H37Rv strain of pyrazinamide, streptomycin, ciprofloxacin were 3.125, 6.25 and 3.125 µg/ml respectively. Whereas, the MIC of serankottai nei was 1.6 µg/ml, which was almost 25 to 50% of standard drugs. Conclusion: Serankottai nei has shown promising antitubercular activity in in-vitro study. Thus, Semecarpus anacardium could be a suitable candidate for a new herbal based antitubercular drug.
Siddha medicine is one of the oldest (5000 years old, pre vedic period) well-documented Indian traditional medicines, compared to Ayurveda, Unani, and traditional Chinese medicine, by way of keen observation and experimentation. It mentions 108 diseases that occur in childhood, which are further classified and described into various subtypes based on the clinical features and different stages of a particular disease. The objective of this review was to collect literature details on pediatric liver diseases and its management as per Siddha medicine. We have referred all the published Siddha books related to the pediatric practice. There were 37 Siddha literature deals pediatric diseases and they use the term kaamaalai or chenkamaari to describe the liver diseases. Most of the literature classifies liver disease into 3 types, but few texts describe 5-6 subtypes. Thus, a total of 9 subtypes of liver diseases in pediatric age group have been described in Siddha literature with a list of herbals to be used for each type. Mostly, the drug therapy is polyhedral formulations of internal and/or external application. A total of 113 herbals, 6 animal products (including black chicken liver, dairy products, donkey's dung, honey) and 7 mineral based products (including iron, rock salt) were listed as potential agents to treat liver diseases. The safety and efficacy of all the above mentioned herbal/mineral products have not been fully explored in children, but may be a great potential for clinical development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.